AUA includes percutaneous tibial nerve stimulation in OAB treatment guidelines

Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that the American Urological Association (AUA) issued a clinical guideline titled "Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults," which includes percutaneous tibial nerve stimulation (PTNS) as an integral part of the care path for overactive bladder (OAB) treatment. The AUA's evidence-based guidelines are intended to promote the highest standards of clinical care. Uroplasty's Urgent® PC Neuromodulation System is the only FDA cleared device that delivers PTNS.

"It is noteworthy that the world's most prestigious urology society has recognized the clinical significance of PTNS in their OAB treatment guidelines," said David Kaysen, President and CEO of Uroplasty.  "We will present these guidelines to the medical directors of U.S. private payers and Medicare carriers as we continue our efforts to expand coverage for our Urgent PC Neuromodulation System."

Source:

Uroplasty, Inc.

Comments

  1. Diana Brown Diana Brown United States says:

    I want to find a doctor in the Chandler, AZ area that does the Perkutaneous Tibial Nerve Stimulation.
    Can you please help me?  My insurance does not cover me at the Mayo Clinic.
    I have been having these sessions which were working great for my over-active bladder and need to continue them down here.
    Please help.
    Thank you,

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Mitochondrial genetics shed light on ALS Risk and protection